BPC
NBIX icon

Bryce Point Capital’s Neurocrine Biosciences NBIX Stock Holding History

Bryce Point Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$597K Buy
+4,254
New +$576K 0.73% 44
2025
Q2 		– Sell
-6,782
Closed -$837K – 238
2025
Q1 		$837K Buy
+6,782
New +$859K 0.63% 76

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bryce Point Capital's NBIX Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Neurocrine Biosciences (NBIX) in Q3 2025: 4,254 shares worth $597K. The stake represents 0.73% of the portfolio and ranks #44 among its holdings. This is a return to the name: Bryce Point Capital previously reported a position in NBIX as recently as Q1 2025.

Bryce Point Capital first reported a position in NBIX in Q1 2025 and has held it in 2 quarters since. The position peaked at $837K in Q1 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Bryce Point Capital held 4,254 shares of Neurocrine Biosciences worth $597K as of Q3 2025.
  • Neurocrine Biosciences was a new Bryce Point Capital position in Q3 2025.
  • Neurocrine Biosciences made up 0.73% of Bryce Point Capital's portfolio in Q3 2025, its #44 holding.
  • Bryce Point Capital first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 2 quarters since.
  • Bryce Point Capital's Neurocrine Biosciences position peaked at $837K in Q1 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.